Pharmacology and clinical evaluation of icotinib hydrochloride

Chinese Journal of New Drugs

Volumn 18, Issue 18, 2009, Pages 1691-1694

  Tan, Fen Lai ^a   Zhang, Li ^b   Zhao, Qiong ^c   Liu, Dong Yang ^b   Hu, Yun Yan ^a   Liu, Yong ^a   Ding, Lie Ming ^a   Hu, Bei ^b   Wang, Yin Xiang ^a  

^a Zhejiang Beta Pharma Inc   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI); Icotinib hydrochloride; Non small cell lung cancer (NSCLC); Pharmacokinetics; Pharmacology

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ICOTINIB; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER PATIENT; CHINA; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG INDICATION; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; REVIEW;

EID: 77955836641     PISSN: 10033734     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (7)

1. GUAN ZM, CHEN XY, WANG YX, et al. Metabolite identification of new antitumor agent Icotinib in rats using liquid chromatograph/tandem mass spectrometry [J]. Rapid Commun Mass Spectrom, 2008, 22(14):2176-2184.
2. th World Conference on Lung Cancer (WCLC). San Francisco, 2009.
3. ZHANG L, JIANG J, LIU DY, et al. Icotinib, a potent and selective oral EGFR inhibitor, is well tolerated and active in patients with NSCLC: results from a phase I/II trial (13th World Conference on Lung Cancer (WCLC). San Francisco.
4. MOK TS, ZHOU C, WU YL, et al. Efficacy and safety of erlotinib in > 1200 East/South-East (E/SE) Asian patients (pts) with advanced non-small-cell lung cancer (NSCLC) [J]. J Clin Oncol, 2008, 26(Suppl): S19001.